Novartis India has reported satisfactory performance during the second quarter ended September 2009 and net profit increased to Rs 33.3 crore from Rs 29.2 per cent, a growth of 14 per cent. Its sales improved by 4.6 per cent to Rs 161.5 crore.

During the quarter under review, its core business, pharmaceuticals with sales of Rs 113.5 crore grew by 7.8 per cent over the corresponding previous period (Rs 105.3 crore). The generics business recorded sales of Rs 10 crore ( Rs 14.4 crore). The animal health business registered sales of Rs 17.4 crore (Rs 13.6 crore). OTC business registered sales of Rs 20.7 crore (Rs 21.1 crore). Profit before tax was marginally lower at Rs 50.4 crore (Rs 50.6 crore).

During the half-year ended September 2009 sales of Rs 314.7 crore registered a marginal growth of 2.1 per cent over sales during the corresponding previous six months period.

During the half-year under review, its core business, pharmaceuticals with sales of Rs 226.1 crore grew by 7.4 per cent over the corresponding previous period (Rs 210.5 crore). The generics business recorded sales of Rs 20.8 crore (Rs 33.1 crore). The animal health business registered sales of Rs 30.2 crore (Rs 24.9 crore). OTC business registered sales of Rs 37.7 crore (Rs 39.7 crore).

Profit before tax was Rs 100.7 crore (Rs 97.4 crore). After providing for tax of Rs 35.7 crore (Rs 38.5 crore), profit after tax stood at Rs 65.0 crore (Rs 58.8 crore).